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ABSTRACT
The treatment of multiple myeloma (MM) has undergone
significant developments in recent years. The availability
of the novel agents thalidomide, bortezomib, and lenalido-
mide has expanded treatment options and has improved
the outcome of patients with MM. Following the introduc-
tion of these agents in the relapsed/refractory setting, they
are also undergoing investigation in the initial treatment of
MM. A number of phase III trials have demonstrated the
efficacy of novel agent combinations in the transplant and
nontransplant settings, and based on these results stan-
dard induction regimens are being challenged and re-
placed. In the transplant setting, a number of newer
induction regimens are now available that have been
shown to be superior to the vincristine, doxorubicin,
and dexamethasone regimen. Similarly, in the front-line
treatment of patients not eligible for transplantation,
regimens incorporating novel agents have been found to
be superior to the traditional melphalan plus pred-
nisone regimen. Importantly, some of the novel agents
appear to be active in patients with high-risk disease,
such as adverse cytogenetic features, and certain co-
morbidities, such as renal impairment. This review pre-
sents an overview of the most recent data with these
novel agents and summarizes European treatment
practices incorporating the novel agents. The Oncologist
2010;15:6–25
INTRODUCTION
Multiple myeloma (MM) is the second most frequent he-
matological malignancy. It is characterized by malignant
plasma cell infiltration of the bone marrow and is associated
with an increased level of monoclonal protein in the blood
and/or urine. The uncontrolled growth of myeloma cells has
many consequences, including skeletal destruction, bone
marrow failure, suppression of normal immunoglobulin
production, and renal insufficiency. Although the disease
remains incurable, outcomes have improved substantially
over recent years as a result of advances in therapy, includ-
ing high-dose therapy and the availability of novel agents,
as well as improvements in supportive care strategies [1, 2].
In parallel with advances in treatment options, the goals
of therapy have also evolved. Although prolongation of dis-
ease-free survival and overall survival (OS) times remain
the ultimate goal, newer, effective therapies are making it
possible to aim for a complete response (CR) in a larger pro-
portion of patients than previously possible. The impor-
tance of achieving a CR for overall outcome has recently
been the subject of discussion. In the transplant setting, the
association between best response and OS has been noted in
a number of analyses [3, 4]. A study by the Spanish my-
eloma group in patients undergoing high-dose therapy
showed that, within the group of patients who achieve dis-
appearance of monoclonal protein, a distinction between
CR and near-CR (nCR) may be important because the
event-free survival (EFS) and OS times were significantly
longer for patients in CR than for patients achieving a nCR
or a partial response (PR) [5]. Moreover, it is not only the
achievement of a CR, per se, but the maintenance of a du-
rable CR that appears to influence outcome, as demon-
strated in a study by Barlogie et al. [6], which showed that
survival was significantly longer in patients who had a du-
rable CR than in those who did not achieve a CR or in those
who achieved CR but subsequently lost their CR status. In
addition, achievement of a CR was found to be particularly
important for patients with high-risk disease by gene-ex-
pression profiling. Interestingly, in a number of trials, a
higher CR rate was not found to correlate with longer sur-
vival [7, 8]. Similarly, CR was not a surrogate marker for
survival in patients whose disease had evolved from mono-
clonal gammopathy of undetermined significance (MGUS)
or smoldering MM [9], although newer data indicate that all
or almost all myelomas arise from a MGUS precursor state.
These results highlight the fact that other considerations
need to be taken into account, such as toxicity, and that CR
may not be the goal in all patients. Although an association
between CR and OS has not been observed in all trials,
achievement of a durable complete remission is an impor-
tant treatment goal that has to be balanced with acceptable
toxicity.
This review aims to provide a summary of recent data
with the novel agents, thalidomide (Thalomid; Celgene
Corporation, Warren, NJ), bortezomib (Velcade; Millen-
nium Pharmaceuticals, Inc., Cambridge, MA), and lena-
lidomide (Revlimid; Celgene Corporation, Warren, NJ),
as well as an overview of current European treatment strat-
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egies, with a focus on these novel agents. There are substan-
tial differences in treatment practices as well as approval
status of these novel agents in the U.S. and Europe (Table
1), and even within Europe the availability of the different
novel agents varies substantially. The manuscript is there-
fore focused on the review of recent data and includes a dis-
cussion of off-label use of these novel agents.
FRONT-LINE TREATMENT
Transplant-Eligible Patients
Induction
For young patients, high-dose therapy with autologous
stem cell support is still considered the standard treatment
following the results of several randomized studies that
demonstrated a survival advantage for patients given this
treatment, compared with conventional chemotherapy [10–
12]. During the 1990s, vincristine, doxorubicin, and dexa-
methasone (the VAD regimen) was considered the standard
induction chemotherapy for MM patients undergoing stem
cell transplantation in most European centers [13]. Re-
sponses to VAD are in the range of 55%–60%; however,
CRs are achieved in only a small number of patients [14],
and moreover, the response to VAD induction has no im-
pact on the outcome after autologous stem cell transplanta-
tion (ASCT) and CRs are typically achieved only post-
transplant.
Recent efforts have focused on improving response
rates, and in particular CR rates, by including novel agents
in induction treatments. Increasing the rate of CRs pretrans-
plant may result in higher rates of CR post-transplant and
superior long-term outcomes. A number of studies, which
will be summarized in the following, are investigating in-
duction regimens incorporating novel agents.
Thalidomide. Thalidomide as short upfront therapy (4-
month duration) was initially administered in combination
with dexamethasone (TD) and was found to be superior to
VAD or dexamethasone alone in terms of the overall re-
sponse rate (ORR); however, the CR rate with the combi-
nation is low, at 4%–10% [15, 16] (Table 2). In addition,
TD has been administered until second ASCT, after initial
treatment with the combination during the induction phase.
A recently reported case-matched analysis found that pa-
tients who underwent this treatment had better clinical out-
comes in terms of a higher CR plus very good partial
response (VGPR) rate, longer time to progression (TTP),
and longer progression-free survival (PFS) time than those
assigned to receive VAD induction plus double ASCT [17]
(Table 2). Thalidomide has also been investigated as part of
three-drug regimens. The Dutch-Belgian Cooperative Trial
Group for Hematology-Oncology (Stichting Hemato-On-
cologie voor Volwassenen Nederland [HOVON]) investi-
gated thalidomide in combination with doxorubicin and
dexamethasone (TAD) and found that TAD resulted in sig-
nificantly higher response rates than VAD postinduction
[18, 19]. In addition, in contrast to the results described by
Macro et al. [20] for TD, the CRVGPR rate remained sig-
nificantly higher for TAD after stem cell transplantation.
Furthermore, there were significantly longer EFS and PFS
Table 1. Approved therapeutic indications for the novel agents thalidomide, bortezomib, and lenalidomide
Europe (http://www.emea.europa.eu) U.S. (http://www.fda.gov)
Thalidomide Thalidomide in combination with melphalan and
prednisone as first-line treatment of patients
with untreated multiple myeloma, aged 65
years or ineligible for high-dose chemotherapy.
Thalidomide in combination with dexamethasone is
indicated for the treatment of patients with newly
diagnosed multiple myeloma.
Bortezomib Bortezomib in combination with melphalan and
prednisone is indicated for the treatment of
patients with previously untreated multiple
myeloma who are not eligible for high-dose
chemotherapy with bone marrow transplant.
Bortezomib for injection is indicated for the
treatment of patients with multiple myeloma.
Bortezomib is indicated as monotherapy for the
treatment of progressive multiple myeloma in
patients who have received at least one prior
therapy and who have already undergone or are
unsuitable for bone marrow transplantation.
Lenalidomide Lenalidomide in combination with
dexamethasone is indicated for the treatment of
multiple myeloma patients who have received at
least one prior therapy.
Lenalidomide in combination with dexamethasone
is indicated for the treatment of multiple myeloma
patients who have received at least one prior
therapy.
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times in the TAD arm; however, there was no difference in
terms of OS between the two arms (Table 2).
Another thalidomide-containing three-drug regimen
was investigated in the Medical Research Council (MRC)
Myeloma IX trial, which was designed to compare cyclo-
phosphamide, thalidomide, and dexamethasone (CTD)
with cyclophosphamide, vincristine, doxorubicin, and
dexamethasone (CVAD) as induction therapy, followed by
a second randomization step between thalidomide mainte-
nance and no maintenance [21, 22]. CTD treatment resulted
in a significantly higher ORR and CR rate than CVAD both
pre- and post-transplant (Table 2).
Taken together, the results suggest that the combination
TD is suboptimal, but that the addition of another chemo-
therapy agent, such as cyclophosphamide or an anthracy-
cline, may improve the outcome.
Bortezomib. Bortezomib has been investigated as part of a
number of different induction regimens. A randomized
phase III study by the French Myeloma Study Group (In-
tergroupe Francophone du Myélome [IFM]) examined the
combination of bortezomib plus dexamethasone and found
this to be significantly superior to the comparator arm,
which consisted of VAD, with respect to response rates
postinduction and post-transplant, as well as the 2-year PFS
rate (Table 3) [23].
In addition, a number of studies are examining bort-
ezomib as part of three-drug induction regimens. For exam-
ple, the Italian Myeloma Network (Gruppo Italiano
Malattie Ematologiche dell’Adulto [GIMEMA]) is investi-
gating bortezomib in combination with thalidomide and
dexamethasone (VTD) compared with TD given before and
after double ASCT. At an interim analysis, VTD was found
to be significantly superior to TD in terms of the CRnCR
and CRVGPR rates pre- and post-transplant, as well as
the PFS rate [24] (Table 3). The combination VTD as in-
duction therapy was also found to be superior in terms of the
postinduction CR rate in a phase III trial investigating the
combination in comparison with TD or VBMCP/VBAD
(vincristine, carmustine, melphalan, cyclophosphamide;
prednisone/vincristine, carmustine, doxorubicin, and dexa-
methasone) plus two cycles of bortezomib, which is being
Table 2. Summary of thalidomide induction trials
Regimen n
Median
follow-up
Postinduction Post-transplant
TTP OS
Major AEs
during
induction Reference
>PR
(%)
>VGPR
(%) >nCR (%)
>PR
(%)
>VGPR
(%) >nCR (%)
Thal/Dex
versus
100 NA 76a NA 13 NA NA NA NA NA DVT, PE,
PN, GI
toxicity
[15]
VAD 100 52 13
Thal/Dex
versus
100 NA NA 35a NA NA 44 NA NA NA DVT, PE,
PN, GI
toxicity
[20]
VAD 104 13 42
Thal/Dex
versus
135 NA NA 30a NA NA 68a NA 4-yr, 61%a 5-yr, 69% DVT, PE,
PN, GI
toxicity
[17]
VAD 135 15 49 4-yr, 41% 5-yr, 53%
Thal/Dex
versus
235 NA 63a 43.8a CR only, 7.7a NA NA NA 22.6 mosa NA DVT, PE,
PN, GI
toxicity
[16]
Dex 235 46 15.8 CR only, 2.6 6.5 mos
TAD versus 267 NA 77a 33a CR only, 4 87a 65a CR only, 30a PFS, 33 mosa 59 mos grade 2–4
neurological,
48%
[18, 19]
VAD 269 54 15 CR only, 2 79 54 CR only, 21 PFS, 25 mos 62 mos grade 2–4
neurological,
29%
CTD versus 1,114 35 mos 87a 39 CR only, 19a 88 67 CR only, 51 NA NA NA [21, 22]
CVAD 75 27 9 87 53 CR only, 40
aStatistically significant difference between arms.
Abbreviations: AE, adverse event; CR, complete response; CTD, cyclophosphamide, thalidomide, and dexamethasone;
CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; Dex, dexamethasone; DVT, deep vein
thrombosis; GI, gastrointestinal; NA, not available; nCR, near complete response; OS, overall survival; PE, pulmonary
embolism; PFS, progression-free survival; PN, peripheral neuropathy; PR, partial response; TAD, thalidomide, doxorubicin,
and dexamethasone; Thal, thalidomide; TTP, time to progression; VAD, vincristine, doxorubicin, and dexamethasone;
VGPR, very good partial response.
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conducted by the Spanish Myeloma Group (Programa para
el Estudio y la Terapéutica de las Hemopatías Malignas y
Grupo Español de Mieloma [PETHEMA/GEM]) [25]
(Table 3).
The Arkansas group pioneered the Total Therapy ap-
proach, and a recent report of long-term follow-up of the Total
Therapy 3 (TT3) regimen, which consists of tandem transplant
with melphalan (200 mg/m2), induction and consolidation
with bortezomib, dexamethasone, thalidomide, cisplatin,
doxorubicin, cyclophosphamide, and etoposide, and mainte-
nance with VTD or bortezomib, lenalidomide, and dexameth-
asone (VRD), demonstrated encouraging results [26]. With a
median follow-up of 39 months, the 4-year EFS rate was 71%
and the 4-year OS rate was 78%. Comparison of the TT3 reg-
imen with that of the predecessor trial, TT2, in which patients
were randomized to receive thalidomide throughout or not, re-
vealed that TT3 was significantly superior in terms of CR and
nCR duration, EFS, and OS.
Another three-drug combination incorporating bort-
ezomib is being examined by the HOVON and the German-
speaking Myeloma Multicenter Group (GMMG). The
ongoing phase III HOVON 65 MM/GMMG-HD4 trial is
comparing bortezomib, doxorubicin, and dexamethasone
(PAD) induction therapy with VAD followed by either bort-
ezomib or thalidomide maintenance treatment post-ASCT
[27]. In a first analysis of the trial, the PAD combination was
found to be significantly superior to VAD in terms of the
VGPR andPR rates (Table 3). Finally, an ongoing phase
II/III trial by the German Myeloma Group (Deutsche Studien-
gruppe Multiples Myelom [DSMM]) is investigating bort-
ezomib, cyclophosphamide, and dexamethasone (VCD) as an
induction regimen based on positive results with the combina-
tion in earlier studies in the relapsed/refractory and upfront set-
tings [28, 29]. Results of an interim analysis of the ongoing
trial demonstrated positive results for the combination [30]
(Table 3).
In summary, a number of bortezomib induction regi-
mens are now available. The results of the IFM trial indicate
that the combination of bortezomib and dexamethasone is
an appropriate regimen that is superior to the traditional
VAD regimen. The addition of thalidomide may further im-
prove response rates, especially CR and VGPR rates, and
possibly the PFS interval. Mature results of the ongoing
studies incorporating anthracyclines and alkylating agents
are eagerly anticipated and will further define the role for
bortezomib-containing induction regimens.
Lenalidomide. A large phase III Eastern Cooperative On-
cology Group (ECOG) trial is investigating lenalidomide in
combination with two different doses of dexamethasone in
Table 3. Summary of bortezomib induction trials
Regimen n
Median
follow-up
Postinduction Post-transplant
TTP OS
Major AEs during
induction (grade 3 or 4)
(%) Reference
>PR
(%)
>VGPR
(%)
>nCR
(%)
>PR
(%)
>VGPR
(%)
>nCR
(%)
Bortezomib Dex
versus
240 2 yrs 82a 39a 15a 91 61a 40a Median, NR;
2-yr PFS, 69%a
2-yr, 90% PN (grade 3 only), 7 [23]
VAD 242 65 16 7 91 44 22 Median, 28 mos;
2-yr PFS, 60%
2-yr, 88% PN (grade 3 only), 2
VTD versus 226 15 mos 94a 62a 32a 76a 55a 2-yr PFS, 90%a 2-yr, 96% PN, 9; skin rash, 7.5 [24]
TD 234 79 29 12 58 32 2-yr PFS, 80% 2-yr, 91% PN, 2.5; skin rash, 1
VBMCP/VBAD
bortezomib
versus
64 NA 72 NA 28 97 NA 54 NA NA PN, 0 Thrombotic events,
5
[25]
VTD versus 56 80 41 97 64 PN, 16 Thrombotic events,
1.7
TD 63 66 12 97 53 PN, 1.5 Thrombotic events,
13
PAD versus 150 NA 79a 45a 7a 91a 71a 26a NA NA PN, 16 [27]
VAD 150 57 17 2 79 44 14 PN, 6
VCD 200 NA 84 NA 12.5
(CR
only)
NA NA NA NA NA PN (overall), 12.5%; PN
(grade 3 only), 0.5%
[30]
aStatistically significant difference between arms.
Abbreviations: AE, adverse event; CR, complete response; Dex, dexamethasone; NA, not available; nCR, near complete
response; NR, not reached; OS, overall survival; PAD, bortezomib, doxorubicin, and dexamethasone; PFS, progression-free
survival; PN, peripheral neuropathy; PR, partial response; TD, thalidomide and dexamethasone; TTP, time to progression;
VAD, vincristine, doxorubicin, and dexamethasone; VBMCP/VBAD, vincristine, carmustine, melphalan,
cyclophosphamide, and prednisone/vincristine, carmustine, doxorubicin, and dexamethasone; VCD, bortezomib,
cyclophosphamide, and dexamethasone; VGPR, very good partial response; VTD, bortezomib, thalidomide, and
dexamethasone.
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the upfront setting. Patients were randomized to receive le-
nalidomide at 25 mg on days 1–21 plus high-dose dexa-
methasone (40 mg on days 1–4, 9–12, and 17–20 every 28
days [RD]) or low-dose dexamethasone (40 mg on days 1,
8, 15, and 22 every 28 days [Rd]) [8]. The primary study
analysis was to compare the two regimens over four cycles
and showed that the RD regimen was associated with a su-
perior ORR and VGPR rate versus Rd (ORR, 79% versus
68%; p  .008 and VGPR, 42% versus 24%; p  .008).
Best responses, including the ORR (81% versus 70%; p 
.009) andVGPR rate (50% versus 40%; p .0001), were
also significantly better for RD. However, the median PFS
time and 2-year OS rate were higher for Rd (median PFS,
25.3 months versus 19.1 months; p  .026 and 2-year OS,
87% versus 75%; p  .0002 for Rd versus RD, respec-
tively), whereas the 3-year OS rate was 75% in both arms
[31]. Among patients who underwent transplantation after
four cycles of primary treatment, the 3-year OS rate was
92%, compared with 55% in those patients who did not un-
dergo transplantation. In addition, among patients who re-
ceived treatment with RD or Rd beyond 4 months, the
3-year OS rate was 79%. However, it has to be noted that
this analysis was not a randomized comparison and that the
trial was not designed to evaluate the combination of lena-
lidomide and dexamethasone as an induction regimen prior
to ASCT. The RD regimen was associated with more tox-
icities than the Rd regimen [8]: Grade3 venous thrombo-
embolisms (VTEs) occurred in 26% versus 12% of patients
(p  .0003), grade 3 infection/pneumonia occurred in
16% versus 9% of patients (p  .04), grade 3 nonhema-
tological adverse events (AEs) were seen in 65% versus
48% of patients (p .0002), and early deaths (4 months)
were observed in 5% and 0.5% of patients, respectively.
Until now, no randomized study has evaluated the combi-
nation of lenalidomide and dexamethasone as an induction
regimen prior to ASCT.
A number of phase I/II and phase II studies are ongoing
that are investigating lenalidomide in different combina-
tions in the upfront setting. Lenalidomide plus bortezomib
and dexamethasone is being investigated by Richardson et
al. [32] and has been found to result in high response rates:
the ORR was 98%, with 71% of patients achieving a
VGPR and 36% of patients achieving a CR/nCR. An on-
going phase II trial is examining the combination of lena-
lidomide and cyclophosphamide [33], whereas the phase
I/II Study of Velcade in Combination with Other Drugs to
Treat Previously Untreated Multiple Myeloma Patients
(EVOLUTION, Evaluation of Velcade, dexamethasone
and lenalidomide with or without cyclophosphamide us-
ing targeted innovative oncology strategies in the treatment
of frontline MM) study is exploring the combination of
bortezomib, dexamethasone, cyclophosphamide, and lena-
lidomide [34]. Initial results suggest that these combina-
tions are active in the setting of newly diagnosed disease,
and results from prospective, randomized studies are
needed to further examine the role of these combinations.
Impact of Novel Agents on Stem Cell Collection
Stem cell mobilization and collection are generally not neg-
atively influenced by thalidomide treatment [35, 36].
Lower stem cell yield has been observed following lena-
lidomide-containing induction therapy [36, 37], and it has
been recommended that stem cell collection be carried out
within 6 months of initiating lenalidomide, or after cyclo-
phosphamide plus G-CSF mobilization, for which no im-
pairment was seen [36–39]. Bortezomib is not long-term
myelotoxic and does not negatively impact stem cell yield
or stem cell mobilization [40]. Adequate collection of pe-
ripheral blood stem cells has been reported.
Post-ASCT Therapy: A Role for Consolidation
and Maintenance?
There are currently no guidelines on post-ASCT therapy
[41, 42]. Thalidomide post-ASCT has been investigated in
a number of randomized trials and has demonstrated benefit
in terms of EFS and PFS; however, the OS time was im-
proved in only some studies (Table 4) [7, 19, 43–49]. Al-
though thalidomide maintenance resulted in significantly
longer survival in patients with cytogenetic abnormalities
in the TT2 setting, it has to be noted that, in that study, con-
ventional cytogenetics were used for the definition of poor
risk and this may have led to the identification of a subgroup
of patients that was not detected in other maintenance stud-
ies [46].
Collectively, these results indicate that, although thalid-
omide consolidation/maintenance results in longer EFS/
PFS times, particularly among patients failing to achieve
high-quality responses after ASCT [43, 44, 47], the effect
on OS is ambiguous, and many open questions remain [50].
The shorter OS duration observed in several studies appears
to be a result of a shorter survival time after relapse, which
may be caused by different factors, such as the duration of
maintenance treatment, the possible selection of more re-
sistant clones, the age of patients, toxicities from previous
treatments, and the availability of salvage treatments. Fu-
ture studies should be aimed at identifying patients who
may benefit from thalidomide maintenance and establish-
ing the appropriate dose and optimal duration of therapy.
Bortezomib was investigated in the maintenance and
consolidation setting in two small studies [51, 52]. Prelim-
inary data suggest that consolidation with VTD may induce
molecular remission in a number of patients [51]. Ongoing
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randomized studies by several European study groups are
further investigating bortezomib as consolidation and
maintenance therapy. For example, the DSMM is investi-
gating the use of bortezomib as consolidation treatment fol-
lowing induction therapy with VCD plus high-dose
therapy. The phase III GIMEMA trial also includes a con-
solidation randomization. Following induction treatment
with VTD or TD and tandem transplantation, patients are
randomized to receive VTD or TD consolidation therapy.
In the HOVON 65 MM/GMMG-HD4 trial, bortezomib
versus thalidomide maintenance therapy is being examined
following initial randomization between PAD and VAD in-
duction.
Patients Not Eligible for Transplantation
Outside the clinical trial setting, treatment for patients
who are not eligible for transplantation has been re-
stricted to the combination of melphalan plus prednisone
(MP) or cyclophosphamide plus prednisone, which leads
to responses in approximately 50% of patients [14]; how-
ever, patients rarely achieve a CR, and long-term out-
comes are disappointing, with a median relapse-free
survival duration of about 18 months and a median OS
time of about 3 years.
Thalidomide
Recently, a number of studies have investigated the addi-
tion of novel agents to the traditional MP regimen. The
combination of MP plus thalidomide has been investigated
in five randomized trials [53–58]. In all studies, the addition
of thalidomide to MP resulted in a significantly greater
ORR, as well as a longer TTP, PFS time, or EFS time (Table
5). A significant benefit in terms of OS, however, was only
seen in the two studies conducted by the IFM [53, 58].
There were some substantial differences in study design,
such as the dose of thalidomide and duration of treatment,
which included maintenance thalidomide in some of the
studies [54–57], but not others [53, 58].
Other combinations have been examined in an attempt
to improve outcomes in the elderly patient group. For ex-
ample, the combination CTD was investigated in a large
trial by the MRC group [21, 48]. Patients received an atten-
uated CTD regimen (CTDa: cyclophosphamide, 500 mg;
thalidomide, 100 mg daily; dexamethasone, 20 mg), which
was compared with MP. Although the CTDa regimen was
superior in terms of the ORR and CR rate, the PFS time was
comparable between the two arms, at 32 months [48].
Dexamethasone-based combinations have also been in-
vestigated in elderly patients with newly diagnosed MM.
Table 4. Summary of thalidomide maintenance studies
Treatment n EFS or PFS OS Survival after relapse Reference
Double ASCT; maintenance:
pamidronate Thal versus
pamidronate versus none,
until disease progression
597 3-yr EFS, 52% versus
37% versus 36% (p
.009)
4-yr, 87% versus 74%
versus 77% (p .04)
Similar in all treatment
groups (p .7)
[43]
Single ASCT; maintenance:
prednisolone Thal versus
prednisolone, 12 mos
243 3-yr PFS, 42% versus
23% (p .001)
3-yr, 86% versus 75%
(p .004)
79% versus 77% (p
.237)
[44]
Double ASCT; maintenance:
Thal versus none, until
disease progression
668 Median, 6.0 versus 4.1
yrs (p .001)
8-yr, 57% versus 44%
(p .09a)
Significantly shorter OS
from relapse after Thal
exposure
[45, 46]
Single or double ASCT;
maintenance: Thal versus
IFN, until disease
progression
556 EFS, 33 versus 22 mos;
p .001. PFS, 33
versus 25 mos (p
.001)
59 versus 62 mos
(p .96)
Significantly shorter OS
from relapse after Thal
exposure
[19]
Single ASCT or
nonintensive therapy (MP
versus CTDa); maintenance:
Thal versus none, until
disease progression
820 Significantly longer PFS
forVGPR after ASCT
(p .007); worse
outcome for Thal
maintenance in patients
with del(17p)
No significant
difference
Significantly shorter OS
from relapse after Thal
exposure
[47, 48]
Thal/Dex versus MP;
maintenance: Thal IFN
versus IFN, until disease
progression
289 PFS, 24 versus 12.6 mos
(p .024)
52.6 versus 52.2 mos
(p .68)
NA [7, 49]
aSignificant difference in patients with cytogenetic abnormalities.
Abbreviations: ASCT, autologous stem cell transplantation; CTDa, attenuated cyclophosphamide, thalidomide, and
dexamethasone; EFS, event-free survival; IFN interferon; MP, melphalan plus prednisone; NA, not available; OS, overall
survival; PFS, progression-free survival; Thal, thalidomide.
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Ludwig et al. [7] investigated the combination TD in com-
parison with MP and found that although TD resulted in
higher a response rate than MP, it was associated with a
shorter OS time and resulted in a higher incidence of toxic-
ity (Table 5), which was observed particularly in patients
75 years old with a poor performance status.
Lenalidomide
Lenalidomide has also been examined in the nontransplant
setting for the treatment of elderly patients with newly di-
agnosed MM. In a phase I/II trial, the combination of lena-
lidomide with MP (MPR) was found to result in an ORR of
81% and a 24% CR rate [59]. With a median follow-up of
29.5 months, the median TTP and PFS times were 28.5
months and the 2-year OS rate was 90.5%. The main AEs in-
cluded neutropenia, thrombocytopenia, and thromboembo-
lism. These preliminary results suggest that the MPR regimen
may be useful in the nontransplant setting; however, confirma-
tion of the results by the ongoing randomized MM015 trial is
needed. In addition, the HOVON and the Nordic Myeloma
Study Group are conducting a phase III trial in elderly patients
comparing melphalan, prednisone, and thalidomide (MPT)
plus maintenance thalidomide with MPR followed by mainte-
nance with lenalidomide, which will further clarify the role of
lenalidomide in the nontransplant setting.
A subanalysis of the phase III ECOG trial examined the
efficacy of RD versus Rd in patients 65 years old. The
1-year survival rate was found to be significantly better for
patients receiving Rd than for those receiving RD (94% ver-
sus 83%, respectively; p .004) [8].
Bortezomib
The combination of bortezomib with MP (VMP) was ex-
plored in the large phase III Velcade as Initial Standard
Table 5. Summary of phase III trials investigating thalidomide combinations in the upfront setting in patients not eligible
for transplantation
Regimen n
Median
follow-
up
CR
PR
(%)
CR
(%) PFS/EFS/TTP (mos)
OS
(mos) Main reported AEs (grade 3 or 4) (%) Reference
Thal/MP
versus
191 51.5 mos 76a 13a 27.5a 51.6a Thromboembolism,
12
Infection, 13 GI, 11 PN, 6 [53]
MP 124 35 2 17.8 33.2 Thromboembolism,
4
Infection, 9 GI, 3 PN, 0
Thal/MP
versus
129 38.1 mos 76a 16a 21.8a 45 Thromboembolism,
12
Infection, 10 GI, 6 PN, 10 [54, 55]
MP 126 48 4 14.5 47.6 Thromboembolism,
2
Infection, 2 GI, 1 PN, 0
Thal/MPb
versus
363 36 mos 42d 6c,d 20a 29 Markedly higher incidence of constipation with Thal [56]
MP 28 3c 18 33 Venous thromboembolism, 8% in both arms
Thal/MP
versus
152 NA 66a 2 EFS 13 versus 9a 37 Thrombosis, 3 Infection, 28 GI, 5 Neurological,
23
[57]
MP 149 47 2 PFS 13 versus 10a 30 Thrombosis, 0 Infection, 18 GI, 7 Neurological,
4
Thal/MP
versus
113 47.5 mos 62a 7a 24.1a 44a Thromboembolism,
6
GIe, 20 PN, 2 [58]
MP 116 31 1 18.5 29.1 Thromboembolism,
3
GIe, 14 PN, 2
Thal/Dex
versus
145 28.1 mos 68a 2 TTP, 21.2 versus 29.1 41.5a DVT/PE, 13 Infection, 13 Constipation/nausea/
vomiting, 13
Neuropathy,
7
[7]
MP 143 50 2 PFS, 16.7 versus 20.7 49.4 DVT/PE, 7 Infection, 8 Constipation/nausea/
vomiting, 6
Neuropathy,
1
CTDa
versus
856 32 mos 82.5a 22.5 No significant
difference for PFS
between arms
NA VTE, 16 [21, 48]
MP 48.7 6.2 VTE, 4.5
aStatistically significant difference between arms.
bThal doses, 200–400 mg.
cCR nCR.
dStatistical information not available.
eGrade 2–4.
Abbreviations: AE, adverse event; CR, complete response; CTDa, attenuated cyclophosphamide, thalidomide, and
dexamethasone; Dex, dexamethasone; DVT, deep vein thrombosis; EFS, event-free survival; GI, gastrointestinal; MP,
melphalan plus prednisone; nCR, near complete response; OS, overall survival; PE, pulmonary embolism; PFS,
progression-free survival; PR, partial response; Thal, thalidomide; TTP, time to progression; VTE, venous
thromboembolism.
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Therapy in Multiple Myeloma: Assessment with Melpha-
lan and Prednisone (VISTA) trial and was found to be sig-
nificantly superior to MP alone for all prespecified
endpoints, including the CR rate, ORR, TTP, and OS time
(Table 6) [60, 61]. VMP was also superior to MP regarding
two additional parameters that were included in the com-
parison of the two arms: time to next therapy (TTNT) and
treatment-free interval (TFI). The TTNT was 28.1 months
for VMP versus 19.2 months for MP (p .000001) and the
TFI was 16.6 versus 8.4 months (p  .000001). Patient
health-related quality of life (HRQoL) data were also col-
lected during the VISTA trial, and an analysis of the asso-
ciation between CR and HRQoL revealed that achievement
of a CR resulted in clinically relevant improvements in sev-
eral aspects of patients’ HRQoL [62]. The main differences
in grade 3 or 4 AEs between the two treatment arms are de-
tailed in Table 6. Peripheral neuropathy (PN) was more fre-
quent in the VMP arm; however, it was reversible in most
patients; 79% of PN events improved (by at least one grade)
in a median of 1.9 months and 60% of PN events com-
pletely resolved in a median of 5.7 months.
A reduced frequency of administration of bortezomib in
combination with MP was investigated in two studies in pa-
tients 65 years old. In a trial conducted by the Spanish
myeloma group, patients were randomized to receive six
cycles of VMP or bortezomib plus thalidomide plus pred-
nisone (VTP) [63]. During cycle 1 of the induction treat-
ment, bortezomib was administered twice weekly, and in
subsequent cycles bortezomib was only administered once
weekly. The results indicate that efficacy was similar be-
tween the two regimens, whereas differences were ob-
served in toxicities (Table 6). Notably, the rate of grade 3 or
4 PN was only 5% with the reduced-dose VMP regimen,
and only 12% of patients discontinued treatment.
The Italian myeloma group also investigated a reduced
frequency of administration of bortezomib in a trial de-
signed to compare bortezomib, melphalan, prednisone, and
thalidomide (VMPT) with VMP in elderly patients [64].
Bortezomib was initially administered twice weekly in a
proportion of patients; however, following a protocol
amendment, all patients received bortezomib once weekly
at 1.3 mg/m2. Efficacy and tolerability results are summa-
rized in Table 6. A comparison of efficacy and toxicity in
patients receiving twice-weekly or once-weekly bort-
ezomib in the VMP arm revealed that a shift from twice-
weekly to once-weekly bortezomib dosing reduced the rate
of CR from 27% to 20%, but that it also substantially re-
duced the incidence of sensory neuropathy (14% versus
2%) and rate of treatment discontinuation (15% versus 4%).
The results of these two studies appear to suggest that a
reduction in bortezomib administration from twice weekly
to once weekly leads to a reduction in toxicity of the VMP
regimen while retaining significant efficacy, although not
at the same level as reported in the original VISTA trial.
Longer follow-up is needed to assess the impact on PFS and
OS.
Table 6. Summary of bortezomib phase III trials conducted in the upfront setting in patients not eligible for transplantation
Regimen n
Median
follow-
up
CR
PR
(%)
CR
(%) TTP OS AEs (grade 3 or 4)c (%) Reference
VMP versus 337 25.9 mos 71a 30a 24 mosa 3-yrb,
72%a
Herpes
zoster, 4
GI, 20 PN, 14 [60, 61]
MP 331 35 4 16.6 mos 3-yrb,
59%
Herpes
zoster, 2
GI, 5 PN, 0
VMP (bortezomib
once weekly)
versus
98 NA 81 22 2-yr, 81% 2-yr,
92%
Neutropenia,
37
Cardiac toxicity, 0 Infections,
7
PN, 5 [63]
VTP (bortezomib
once weekly)
107 81 27 2-yr, 83% 2-yr,
94%
Neutropenia,
21
Cardiac toxicity,
8.5
Infections,
1
PN, 9
VMP (bortezomib
once weekly)
versus
229 16.1 mos 78 21a 3-yr PFS,
56%
3-yr,
89%
Neutropenia,
28
Thrombocytopenia,
16
Infections,
7
PN, 2 [64]
VMPT (bortezomib
once weekly)
221 84 35 3-yr PFS,
71%
3-yr,
90%
Neutropenia,
28
Thrombocytopenia,
20
Infections,
12
PN, 2
aStatistically significant difference between arms.
bMedian OS not reached in either arm.
cMajor AEs/AEs that differ between arms.
Abbreviations: AE, adverse event; CR, complete response; GI, gastrointestinal; MP, melphalan plus prednisone; NA, not
available; OS, overall survival; PFS, progression-free survival; PN, peripheral neuropathy; PR, partial response; TTP, time
to progression; VMP, bortezomib, melphalan, and prednisone; VMPT, bortezomib, melphalan, prednisone, and thalidomide;
VTP, bortezomib, thalidomide, and prednisone.
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SPECIFIC TREATMENT SITUATIONS
Renal Impairment
Renal impairment is a serious complication of MM, which
affects a major subgroup of patients. Renal impairment re-
quires fast-acting myeloma treatments to reduce tumor bur-
den, with manageable adverse effects that do not further
impair the kidneys, or in some cases even allow for recov-
ery of renal function.
In a number of studies, bortezomib was found to be a
useful agent in the setting of renal impairment. It has a rapid
onset of action and, importantly, its elimination is indepen-
dent of renal clearance [65], indicating that dose adjust-
ments are not necessary in patients with renal impairment,
including those requiring dialysis [66]. In addition, bort-
ezomib may directly act against myeloma kidney disease
through its inhibition of nuclear factor B, the overactiva-
tion of which is thought to be a marker of progressive renal
disease in humans [67]. Bortezomib may thus reduce in-
flammation in myeloma kidney disease [68]. In a number of
subanalyses, bortezomib efficacy and tolerability were
found to be comparable in both young and elderly patients
with varying stages of renal impairment and in those with
normal renal function [69–71]. Importantly, improvement
in renal function has been observed, suggesting that bort-
ezomib may possibly help to normalize renal dysfunction in
selected patients. In an ongoing prospective phase II study
in patients with acute renal failure, conducted by Ludwig et
al. [72], bortezomib in combination with doxorubicin and
dexamethasone was found to result in renal responses in
62% and complete renal responses (glomerular filtration
rate60 ml/minute) in 31% of patients.
Thalidomide is also considered a feasible option for the
treatment of patients with renal impairment. An analysis of
pharmacokinetic data in patients with varying degrees of re-
nal function found that there was no correlation between
thalidomide clearance and renal function [73]. In addition,
clinical studies have shown that response rates and tolera-
bility with thalidomide are similar in patients with renal
failure and in those with normal renal function, both in the
relapsed/refractory and front-line settings [74, 75]. In addi-
tion, recovery of renal function was observed in the major-
ity of patients whose disease responded to thalidomide
treatment [74].
Lenalidomide is primarily excreted by the kidneys and,
therefore, careful monitoring of AEs and appropriate dose
adjustments in patients with impaired renal function are es-
sential [76–79]. Prospective studies investigating lenalido-
mide dose adapted to creatinine clearance have been
initiated.
Cytogenetic Abnormalities
MM is characterized by various chromosomal changes that
carry prognostic information. The deletion of chromosome
17 [del(17)], the translocation of chromosomes 4 and 14
[t(4;14)], the translocation of chromosomes 14 and 16
[t(14;16)], as detected by fluorescence in situ hybridization,
the deletion of chromosome 13 [del(13)] by metaphase cy-
togenetics, and the presence of hypodiploidy are character-
istic of high-risk disease [80]. Novel agents may offer the
possibility of improving outcomes in patients with these ad-
verse prognostic factors.
Bortezomib appears to be effective in patients with cy-
togenetic abnormalities, as observed in a number of studies.
In the relapsed/refractory setting, the ORR, duration of re-
sponse, and OS time were not found to be different between
patients with and without del(13) [81, 82]. In elderly pa-
tients with newly diagnosed disease, the response rate,
TTP, and OS time were not negatively affected by the pres-
ence of t(4;14), t(14;16), or del(17p) [60]. In the transplant
setting, bortezomib induction regimens were also found to
remain effective in patients with cytogenetic abnormalities.
In the IFM bortezomib plus dexamethasone versus VAD
study, the combination of bortezomib plus dexamethasone
resulted in a significantly higherVGPR rate than VAD in
patients with t(4;14) and/or del(17p) [23]. Similarly, in an
Italian trial investigating a bortezomib-based induction reg-
imen, the combination of VTD was significantly superior to
TD in patients with t(4;14) and in those with del(17p) in
terms of the CRnCR rate [83].
The addition of thalidomide to the TT2 regimen was found
to result in significantly longer survival in patients with cyto-
genetic abnormalities than in patients who did not receive tha-
lidomide [46]. On the other hand, Cavo et al. [84] showed that
TD resulted in a significantly lower probability of response in
patients with co-existing del(13) and t(4;14), but not in those
with a single abnormality. Moreover, a recent examination of
thalidomide maintenance therapy in the MRC Myeloma IX
trial found that, in patients with del(17), thalidomide treatment
was unfavorable [22, 47].
Lenalidomide has also been investigated in patients
with cytogenetic abnormalities. Results from a study by Re-
ece et al. [85] in patients with relapsed/refractory MM in-
dicated that t(4;14) did not influence the response rate, TTP,
or OS time, whereas in patients with del(17), the TTP and
OS time were significantly shorter. A recent report by the
IFM suggested that, in heavily pretreated patients with re-
lapsed or refractory MM, the presence of t(4;14) resulted in
a significantly lower response rate and shorter PFS and OS
times than in patients without cytogenetic abnormalities
[86]. Finally, a report by Kapoor et al. [87] showed that le-
nalidomide treatment resulted in comparable response rates
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in patients with newly diagnosed high-risk and standard-
risk disease; however, responses were less durable in pa-
tients with high-risk disease and the PFS interval was
significantly shorter in those patients. However, the OS
time was not significantly different between the high-risk
and standard-risk groups.
For all novel therapies, there is a lack of prospective data in
patients with cytogenetic abnormalities. Currently available
results are obtained from reports with small patient numbers
and are often derived from subanalyses of trials. Overall, pro-
spective studies with larger patient numbers and longer fol-
low-up are needed to establish the role of novel agents in this
setting to enable a risk-adapted approach.
TREATMENT DECISIONS FOR NEWLY
DIAGNOSED DISEASE
Decision trees for the front-line treatment of MM have been
developed, and Figure 1 shows a possible treatment tree
based on available data from novel agents. The initial deci-
sion in newly diagnosed disease is whether the patient is el-
igible for transplantation or not. In patients 65 years old
and without comorbidities, ASCT after a short induction
course (three or four cycles) is considered the standard of
care. In recent years, a large number of studies have focused
on improving outcomes of transplantation by adding novel
agents. In particular, incorporation of novel agents into in-
duction regimens has been studied extensively with a range
of different combinations in an effort to improve pre- and
post-transplant response rates, especially CR or VGPR
rates, because the achievement of a CR is associated with a
superior overall outcome. Although long-term survival data
are still lacking, the majority of studies involving novel
agents have demonstrated superior CRVGPR rates, com-
pared with VAD postinduction and post-transplant, sug-
gesting that this traditional regimen should no longer be
considered standard. Instead, induction regimens should
contain at least one novel agent, and ongoing and future
studies will establish if three-agent regimens are superior to
Figure 1. MM treatment tree outside clinical trials: front line.
*Indicates data available from a phase III randomized trial.
Abbreviations: CTD, cyclophosphamide, thalidomide, and dexamethasone; CTDa, attenuated cyclophosphamide, thalido-
mide, and dexamethasone; Cyc, cyclophosphamide; Dex, dexamethasone; IMiD, immunomodulatory drug; Len, lenalidomide;
MM, multiple myeloma; MP, melphalan plus prednisone; MPR, melphalan, prednisone, and lenalidomide; MPT, melphalan, pred-
nisone, and thalidomide; PAD, bortezomib, doxorubicin, and dexamethasone; PN, peripheral neuropathy; Pred, prednisone; Rd,
lenalidomide plus low-dose dexamethasone; SCT, stem cell transplant; TAD, thalidomide, doxorubicin, and dexamethasone;
Thal, thalidomide; TT3, Total Therapy 3; VCD, bortezomib, cyclophosphamide, and dexamethasone; VDT-PACE, bortezomib,
dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide; VGPR, very good partial response; VMP,
bortezomib, melphalan, and prednisone; VRD, bortezomib, lenalidomide, and dexamethasone; VTD, bortezomib, thalidomide,
and dexamethasone.
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two-agent combinations. Based on the data from random-
ized, phase III studies, the following regimens can be rec-
ommended over VAD: bortezomib plus dexamethasone,
VTD, CTD, PAD, and TAD. TD appears to be similar to
VAD in terms of efficacy and may therefore be suboptimal.
Other combinations, such as VCD and VRD, are currently
undergoing investigation, and data from randomized stud-
ies are needed before these regimens can be recommended
outside clinical trials. Finally, further data are needed re-
garding combinations, such as bortezomib plus CTD and
Rd.
Treatment decisions need to take into account consider-
ations of patient or disease factors, such as the presence of
high-risk disease, comorbidities, and other complications.
In cases of renal impairment, bortezomib-based combina-
tions may be the treatment of choice because of accumulat-
ing data demonstrating the positive effect of this agent in
this setting. In cases of pre-existing clinical PN, a lenalido-
mide-containing combination may be useful because lena-
lidomide is not neurotoxic, whereas a history of VTEs may
indicate bortezomib use. In patients with high-risk cytoge-
netic abnormalities, particularly del(17p) and t(4;14), bort-
ezomib has been shown to be effective; however, results
from larger trials are needed before recommendations can
be given. In addition, more mature data on lenalidomide in
this setting are also needed.
Regarding post-transplant therapy, there is currently a
lack of strong recommendations, and results from ongoing
trials incorporating novel agents are awaited. In cases of the
achievement of at least a VGPR following SCT, the options
are to not administer any treatment or to consolidate or
maintain the response with one of the novel agents, such as
thalidomide or a bortezomib-based combination, for which
preliminary results appear promising. In cases of a response
less than a VGPR following SCT, it is feasible to consider a
second transplant or consolidation with thalidomide. How-
ever, there are questions regarding the optimal dose or du-
ration of treatment with thalidomide that have to be
answered in future studies. Furthermore, certain factors,
such as the presence of del(17) may render thalidomide less
useful in the setting of maintenance/consolidation. Other
novel agent combinations can also be considered in this set-
ting, and a number of studies are currently ongoing that
should deliver results in the near future.
In elderly patients and those not eligible for transplan-
tation, results of recent trials indicate that MP should no
longer be considered the standard, but that this should be
supplemented with novel agents, based on the results of
randomized phase III trials. MPT, VMP, and CTDa have
been shown to significantly improve outcomes over MP. In
addition, the combination of lenalidomide and dexametha-
sone may be a valuable option for the treatment of elderly
patients. A trial comparing MPR with MP was recently
closed and results of that study will contribute to defining
the role of lenalidomide in this setting.
The group of patients who are not eligible for transplan-
tation is diverse, and it is important to differentiate between
those patients who are fit enough to tolerate a full-dose reg-
imen and those patients who are frail and for whom a less
intensive treatment approach may be useful to minimize
toxicities and optimize treatment duration. Treatment
should be selected based on biological age, comorbidities,
and overall clinical impression.
The VMP regimen with a reduced frequency of admin-
istration of bortezomib may be useful in the frail patient
population; however, long-term survival data are needed
before firm recommendations can be given. Furthermore,
dose-adjusted MPT and low-dose lenalidomide-based com-
binations are also options in these patients, although there is
currently little evidence for lenalidomide in this setting.
TREATMENT AT RELAPSE
In the majority of cases, MM relapses, even if long periods
of remission can be achieved. Prior to the arrival of novel
agents, the outcome for patients with relapsed/refractory
disease was usually disappointing; however, since novel
agents have become available, the outlook for patients has
improved steadily, as demonstrated in a recent analysis by
Kumar et al. [2].
Since the first report of the activity of thalidomide in the
treatment of MM [88], a large number of studies have in-
vestigated this agent further in the setting of relapsed/re-
fractory disease. Single-agent activity is limited, and the
agent is typically used in combination with dexamethasone
and/or chemotherapy [89]. The major toxicities in relapsed
disease mirror those in the front-line setting and include
PN, deep vein thrombosis, sedation, and gastrointestinal
AEs. Although the agent is widely used in the treatment of
relapsed/refractory MM, it is not approved for this indica-
tion.
Bortezomib monotherapy was investigated in the phase
III Assessment of Proteasome Inhibition for Extending Re-
missions (APEX) trial and was found to be significantly su-
perior to high-dose dexamethasone in terms of the ORR,
CRnCR rate, TTP, and OS time, despite 62% of pa-
tients in the dexamethasone arm crossing over to receive
bortezomib [90] (Table 7). In another phase III trial, the ad-
dition of pegylated liposomal doxorubicin (PegLD)
(Doxil; Ortho Biotech Products, L.P., Bridgewater, NJ) to
bortezomib was found to lead to a significantly longer TTP
and OS time versus bortezomib alone [91]. A large number
of studies have examined bortezomib in combination with
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steroids, conventional chemotherapy, or other novel agents
and have demonstrated superior efficacy resulting from ad-
ditive or synergistic effects [92–95]. Major toxicities with
bortezomib in the relapsed setting include thrombocytope-
nia, neutropenia, PN, and gastrointestinal AEs. In the re-
lapsed setting, bortezomib is indicated in the European
Union for the treatment of MM at first relapse as a single
agent, but clinically, it is almost universally used in combi-
nation.
Retreatment with bortezomib was examined in the pro-
spective phase II Retreatment after Initial Response to Vel-
cade (RETRIEVE) study, in which patients whose disease
had responded to previous bortezomib treatment and re-
lapsed after6 months could be retreated with bortezomib
(with or without dexamethasone) [96]. Preliminary results
of that study indicate that responses were achieved in ap-
proximately two thirds of patients and that retreatment is
well tolerated with no evidence of cumulative toxicity. In
addition, an analysis of response to treatment at relapse in
the phase III VISTA trial demonstrated that retreatment
with bortezomib appears feasible and that patients can also
be effectively treated with immunomodulatory drugs
(IMiDs) following front-line bortezomib [61].
Lenalidomide is licensed for the treatment of relapsed/
refractory disease in combination with dexamethasone,
based on two phase III studies (the MM009 and MM010
studies) that demonstrated a significantly greater ORR, CR
rate, TTP, and OS time for the combination versus dexa-
methasone alone, despite 47.6% of patients in the dexa-
methasone group crossing over to receive lenalidomide
plus dexamethasone (Table 7) [97–99]. The main toxicities
reported with the combination of lenalidomide plus dexa-
methasone include neutropenia, thrombocytopenia, VTE,
and infection [97, 98]. An analysis of the effects of prior
thalidomide exposure on response, TTP, and OS with lena-
lidomide plus dexamethasone revealed that the combina-
tion remained significantly superior to dexamethasone
alone regardless of prior thalidomide [100]. In patients who
were refractory to thalidomide, treatment with lenalido-
mide plus dexamethasone was associated with a lower CR
rate and ORR and shorter TTP and PFS time than in those
with thalidomide-sensitive disease.
Lenalidomide is also being investigated in combination
with other agents, such as doxorubicin, cyclophosphamide,
and bortezomib and also in combination with thalidomide.
In general, response rates with these combination regimens
are superior to those seen with lenalidomide plus dexameth-
asone alone. For example, the combination of lenalido-
mide, doxorubicin, and dexamethasone, which was
investigated in a phase I/II study in 69 patients, resulted in
an ORR of 73% in the overall population, including a
14.5% CR rate and 43% VGPR rate [101]. The median TTP
was 10.4 months and the 1-year survival probability was
88%. Longer follow-up is needed to assess the effects on
OS in this and other combination studies.
SCT at Relapse
The use of ASCT at relapse has been investigated in a num-
ber of studies [102–107] and is considered a useful option in
selected patients [107]. Its success appears to be influenced
by the efficacy of the previous transplant, the number of
prior therapies, as well as the time between the initial and
the second transplant step.
Furthermore, allogeneic stem cell transplantation (allo-
Table 7. Summary of phase III trials in the relapsed/refractory setting
Treatment n
Median
follow-up
CR
PR
(%)
CR
nCR
(%)
TTP
(mos) OS Reference
Bortezomib versus 333 22 mos 43a 16a 6.2a 29.8 mosa [90]
Dex 336 18 2 3.5 23.7 mos
Bortezomib/pegylated
liposomal doxorubicin
versus
318 NA 52a 17 9.3a 15-mo OS,
76%a
[91]
Bortezomib 318 44 13 6.5 15-mo OS,
65%
Lenalidomide/Dex versus 353 48 mos 60.6a 15a,b 13.4a 38 mosa [97–99]
Dex 351 21.9 2 4.6 31.6 mos
aSignificant difference between arms.
bCR only.
Abbreviations: CR, complete response; Dex, dexamethasone; nCR, near complete response; OS, overall survival; PR,
partial response; TTP, time to progression.
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SCT) may also be feasible in the relapsed setting, and this
approach was investigated in a number of recent studies
[108 –110]. It has been suggested that allo-SCT may be
valuable in patients with high-risk disease, but that it cur-
rently remains an investigational approach [111].
TREATMENT DECISIONS AT RELAPSE
Figure 2 shows a possible treatment decision tree for the
treatment of MM at relapse, with a focus on incorporating
novel agents into the treatment. It is notable that, although
novel agents are widely incorporated into treatment at re-
lapse, data supporting their use does not always stem from
randomized studies. Nevertheless, their use is associated
with better outcomes [2], and at relapse after front-line
treatment with one of the “older” agents, administration of
a novel agent should be considered.
Increasingly, novel agents are being incorporated into
front-line treatments, which will significantly influence the
choices available at relapse and may also influence the ef-
ficacy of the different treatments.
A decision to be made at relapse is whether to repeat the
initial front-line treatment or switch to a therapy different from
that used previously. The decision will be influenced by the
duration of remission to initial therapy as well as by the pres-
ence of or risk for toxicities. If a long remission was obtained
(12 months) following a distinct short course of treatment
and AEs were acceptable, then rechallenge with the front-line
regimen may be possible. On the other hand, if only a short
remission (6 months) was obtained and the duration of the
initial therapy was long, then it may be advisable to switch to a
different treatment. For example, transplant at relapse is feasi-
ble if a long remission was achieved with the initial transplant.
Increasingly, novel agents are being incorporated into front-
line therapies, and treatment at relapse has to consider the ap-
propriate treatment sequence. If the relapse happened after
long-term thalidomide treatment, then it would be advisable to
change treatment and consider a bortezomib-based regimen
with the potential addition of alkylating agents. If the disease
recurred after front-line treatment with bortezomib, a switch to
an IMiD-containing regimen may be indicated. Alternatively,
Figure 2. MM treatment tree outside clinical trials: relapse.
*Indicates data available from a phase III randomized trial.
Abbreviations: allo-SCT, allogeneic stem cell transplantation; auto-SCT, autologous stem cell transplantation; CRD, cyclo-
phosphamide, lenalidomide, and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; CVD, cyclophos-
phamide, bortezomib, and dexamethasone; Cyc, cyclophosphamide; Dex, dexamethasone; Len, lenalidomide; MPT, melphalan,
prednisone, and thalidomide; PAD, bortezomib, doxorubicin, and dexamethasone; PegLD, pegylated liposomal doxorubicin; PN,
peripheral neuropathy; Thal, thalidomide; VMP, bortezomib, melphalan, and prednisone; VTD, bortezomib, thalidomide, and
dexamethasone.
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retreatment with bortezomib may be considered if a good re-
sponse to the initial bortezomib therapy was obtained and if
the treatment-free interval was long.
The presence of toxicities will influence the choice of treat-
ment at relapse and may necessitate a change from the front-
line treatment. For example, if PN is present from front-line
treatment, a switch to a non-neurotoxic agent, such as lenalido-
mide, may be necessary. The combination of lenalidomide and
dexamethasone can be considered a reasonable treatment in
thalidomide-refractory patients if PN is present. A history of or
high risk for thromboembolic events may indicate a switch
from an IMiD-based regimen to a bortezomib combination
and the use of low molecular weight heparin (LMWH) throm-
bophylaxis to avoid further complications.
Specific disease characteristics also influence treatment
decisions at relapse, for example, in cases of an aggressive
relapse and the presence of poor-risk cytogenetics, treat-
ment with bortezomib or lenalidomide may be indicated. In
the presence of renal impairment, a bortezomib-containing
regimen may be useful.
In choosing the optimal treatment at relapse, the deci-
sion should be individualized based on patient-specific
characteristics such as age, presence of comorbidities, type
of previous therapy, quality and duration of response, tol-
erance of therapy, and time without treatment. In addition,
decisions have to be made regarding the sequential use of
different agents versus combination treatment with simul-
taneous administration of several agents. Novel agents that
have been shown to offer better outcomes than traditional
regimens should, whenever feasible, be incorporated into
the treatment strategy.
MANAGING AES ASSOCIATED WITH NOVEL
AGENT USE
Thromboembolic events are one of the most significant side
effects associated with thalidomide or lenalidomide when
these agents are used in combination with steroids or che-
motherapy. The risk for developing thromboembolic events
appears to be greater when erythropoiesis-stimulating
agents (ESAs) are added to IMiDs [112].
Thromboprophylaxis consists of aspirin, LMWH, or
warfarin given at either the full dose or a fixed low dose. In
a phase III study, fixed low-dose warfarin was not inferior
to LMWH or aspirin in patients with a low risk for devel-
oping thromboembolic events [113]. On the other hand,
LMWH may be recommended in patients at higher risk for
developing this complication and in those receiving con-
comitant high-dose dexamethasone or doxorubicin [114].
Studies are needed to define the optimal agent in the differ-
ent settings. Prior history or a risk for developing thrombo-
embolic events will require the use of thromboprophylaxis
in combination with the chosen IMiD. Alternatively, bort-
ezomib may be useful in this setting because this agent is
not associated with a higher risk for thromboembolic events
[115], even with the use of ESAs [116].
Both bortezomib and thalidomide can lead to PN, which
can be debilitating in some patients. It has been observed
that patients who do not develop PN during the first four to
six cycles of bortezomib treatment are unlikely to develop
this complication during further bortezomib treatment cy-
cles. Notably, bortezomib-associated PN is reversible in the
majority of patients. In the APEX trial, grade 2 PN re-
solved or improved in 64% of patients, whereas in the
VISTA trial improvement by at least one grade was ob-
served in 79% of patients in a median of 1.9 months [61,
117]. Complete resolution was seen in 60% of patients
within a median of 5.7 months. Close monitoring of patients
and dose reduction at the first sign of a worsening of the
tingling sensation are important. It may be useful to employ
a specific questionnaire to help patients recognize the
symptoms and to detect the early signs of PN [118].
The risk for developing PN while receiving thalidomide
increases with prolonged administration [89]. Dose reduc-
tion or discontinuation of treatment is necessary to manage
the complication [89]. Lenalidomide is not associated with
PN and it may therefore be useful for the treatment of pa-
tients with pre-existing PN.
Bortezomib therapy can be associated with reactivation
of varicella zoster virus (herpes zoster) [61, 119]; however,
the use of antiviral prophylaxis has been shown to success-
fully prevent this AE [120], and the routine use of antiviral
prophylaxis in patients receiving a bortezomib-containing
regimen should therefore be considered [119].
Neutropenia is frequently observed with lenalidomide
treatment and may necessitate dose reduction, discontinua-
tion of treatment, or administration of growth factors [59,
79, 121, 122]. Bortezomib treatment can lead to thrombo-
cytopenia, which may require dose reduction or temporary
treatment discontinuation. However, bortezomib-induced
thrombocytopenia is cyclical and platelets typically recover
during the rest period of a treatment cycle, so that interven-
tion may not be necessary [66, 115].
MM is characterized by bone disease, and bisphospho-
nates play an important role in the management of skeletal
events. Expert recommendations regarding the use of
bisphosphonates have been formulated and were recently
published [123]. In patients suffering from lytic bone dis-
ease, the use of bisphosphonates is recommended. Treat-
ment should be administered for 2 years and proactive
management is needed to avoid renal impairment and os-
teonecrosis of the jaw.
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CLINICAL GAPS AND ONGOING RESEARCH
A number of questions surrounding the use of novel agents in
the treatment of MM remain. For example, long-term fol-
low-up of the front-line trials is needed so that treatment deci-
sions can be made based on robust survival data. Long-term
data will provide answers to questions such as the optimal in-
duction treatment and the appropriate sequencing of agents.
Furthermore, new classes of antimyeloma agents, such as heat
shock protein-90 and histone deacetylase inhibitors, have
shown promising results in preclinical studies and are cur-
rently undergoing investigation in the clinical setting. The
combination of these newer agents with the agents discussed
herein appears attractive and may offer better outcomes.
Studies are needed to further explore the role of trans-
plantation and of consolidation and maintenance therapy.
Regarding risk-adapted treatment approaches, large trials
or systematic reviews of the available data are needed to de-
fine the role of the different agents in the setting of high-risk
disease and provide treatment recommendations according
to risk factors, such as cytogenetic abnormalities. In addi-
tion, further advances in techniques, such as gene-expres-
sion profiling and single-nucleotide polymorphism
analysis, are eagerly anticipated to further individualize
treatment approaches for patients. Moreover, there may be
a role for minimal residual disease detection in deciding on
the intensity of induction therapy and on the duration of
maintenance therapy. Finally, assessment of quality of life
has so far been given insufficient attention in MM studies
and future studies will help to close this gap.
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